会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • MONOMERIC PROTEINS AND USES THEREOF
    • 单体蛋白质及其用途
    • WO2017191439A1
    • 2017-11-09
    • PCT/GB2017/051212
    • 2017-04-28
    • LIVERPOOL SCHOOL OF TROPICAL MEDICINE
    • PLEASS, RichardBLUNDELL, Patricia
    • C07K16/00A61K39/395C07K14/435C12N15/62
    • Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and/or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use.
    • 提供了包含两条嵌合多肽链的蛋白质; 其中每个嵌合多肽链包含含有两个免疫球蛋白G重链恒定区的Fc受体结合部分; 和免疫球蛋白尾部区域。 与野生型免疫球蛋白的序列和糖基化相比,蛋白质尾部区域的氨基酸序列和糖基化适合于抑制蛋白质的聚合。 氨基酸序列的适应可以是缺失半胱氨酸残基,例如对应于SEQ ID NO:1的残基248的半胱氨酸残基。蛋白质可用于静脉内免疫球蛋白(IVIG)或皮下免疫球蛋白(SCIG)治疗 。 它们可用于预防或治疗通过结合唾液酸依赖性受体介导的疾病。 本发明的蛋白质可用于预防和/或治疗自身免疫疾病或炎症疾病。 蛋白质可以与免疫调节剂结合,并且在这种情况下适用于疫苗使用。
    • 10. 发明申请
    • POLYMERIC PROTEINS AND USES THEREOF
    • 聚合蛋白及其用途
    • WO2016009232A1
    • 2016-01-21
    • PCT/GB2015/052098
    • 2015-07-20
    • LIVERPOOL SCHOOL OF TROPICAL MEDICINE
    • PLEASS, RichardBLUNDELL, Patricia
    • C07K16/46A61K39/395
    • C07K16/46C07K2317/21C07K2317/35C07K2317/41C07K2317/52C07K2317/524C07K2317/53C07K2317/60C07K2317/94C07K2319/00
    • Provided are polymeric proteins that comprise two or more polypeptide monomer units, each monomer unit comprising two chimeric protein chains. Each chimeric polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions,wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit. Each chimeric protein chain also comprises a modified immunoglobulin M tailpiece region, wherein the amino acid sequence of each chimeric polypeptide monomer comprises an alteration of the primary structure as compared to the native sequences from which the immunoglobulin G heavy chain constant region or immunoglobulin M tailpiece region are derived, and the alteration changes the number of glycosylation sites in a manner that promotes polymerisation. This promotion of polymerisation may lead to the generation of tetrameric, hexameric, and even dodecameric forms of the proteins. The proteins are suitable formedical uses,such as in the prevention or treatment of autoimmune diseases such as idiopathic thrombocytopenia. Also provided are methods of treatment using the polymeric proteins, and pharmaceutical compositions comprising the polymeric proteins.
    • 提供包含两个或更多个多肽单体单元的聚合蛋白质,每个单体单元包含两个嵌合蛋白质链。 每个嵌合多肽单体单元包含Fc受体结合部分,其包含两个免疫球蛋白G重链恒定区,其中每个免疫球蛋白G重链恒定区包含通过二硫键与免疫球蛋白G重链常数的半胱氨酸残基连接的半胱氨酸残基 相邻多肽单体单元的区域。 每个嵌合蛋白链还包含修饰的免疫球蛋白M尾部区域,其中每个嵌合多肽单体的氨基酸序列与免疫球蛋白G重链恒定区或免疫球蛋白M尾端区域的天然序列相比包含一级结构的改变 并且改变以促进聚合的方式改变糖基化位点的数目。 聚合的这种促进可能导致四聚体,六聚体,甚至十二聚体形式的蛋白质的产生。 蛋白质是合适的形式用途,例如预防或治疗自身免疫性疾病如特发性血小板减少症。 还提供了使用聚合蛋白的治疗方法和包含聚合蛋白的药物组合物。